



Premature termination of a Clinical Trial

Full title of the clinical Trial:

Acute effects of ketamine on the glutamatergic NMDA receptor quantified by PET and the radioligand (R)-[¹¹C]-Me-NB1

EudraCT Number:

2022-003266-21

Sponsor: Medical University of Vienna
Represented by (name):

Univ.-Prof. PD MD Rupert Lanzenberger

Reason for premature termination of the clinical trial:

Due to substantial construction delays in the PET facilities of the Department for Nuclear Medicine, radiotracer production has not been possible and is still not for the foreseeable future. Furthermore, there were important changes in staff and insufficient funding. Because of this, recruitment for the main study could not yet start. Therefore, the study will be terminated.

Study results (if available):

Recruitment of the trial could not yet start and no data have been collected.

Prof. PD-Dr.med. Rupert Lanzenberger, MD
Head, NEUROIMAGING LABs (NIL) - PET & MRI & EEG & Chemical Lab
Department of Psychiatry and Psychotherapy, MEDICAL UNIVERSITY OF VIENNA
Wehringer Gürtel 18-20, A-1080 Wien, Austria
Phone: +43 (1) 40 400 - 35760 / E-mail: rupert.lanzenberger@meduniwien.ac.at
<http://www.meduniwien.ac.at/neuroimaging/>

Date and Signature of Sponsor representative:

04.02.2025